In-house & bespoke training:
Biopharma

Biopharmaceuticals, known colloquially as biopharma, are the point at which biotechnology and pharmaceutical manufacturing meet. Biopharma is the application of living organisms or extractions, by-products or components of living organisms, to prevent, relieve, or treat diseases.

Management Forum’s biopharma training courses provide an extensive series of training opportunities covering a variety of topics, including the development of biopharmaceuticals, clinical trial requirements, manufacture, regulations and applicable standards. Our courses also provide insight into the use of emerging technologies and state-of-the-art processes.  

 

Please note: full product details will be shown on our training portal IPI Academy where you can find out more and book

Biosimilars

In-house & bespoke training

A two-day seminar providing an essential overview of biosmilars and how they differ from the original biological product.

Rated by attendees to the public programme

Typically presented by Andrew Willis (bio)

Typical duration: 2 days
Pricing from £800 per attendee
Delivery: collaborative classroom

More @ IPI Academy

Biotechnology for the Non-Biotechnologist

In-house & bespoke training

An ideal course for non-scientists and scientists who need to understand the basic theory, principles, techniques and potential of biotechnology.

Rated by attendees to the public programme

Typically presented by Robert Alvarez (bio)
and 6 more leading experts

Typical duration: 3 days
Pricing from £1,200 per attendee
Delivery: collaborative classroom

More @ IPI Academy

Chemistry, Manufacture and Control (CMC) - Regulatory Requirements for Biological Drug Products

In-house & bespoke training

The regulatory requirements for Biological drug products are complex, and pharmaceutical companies are continuously under pressure to ensure regulatory compliance from drug discovery to post-marketing surveillance.
This course has been designed to help you navigate the complex regulatory requirements for biological drugs, including ATMPs. It will clearly depict the differences between small and large molecules and the development approaches which reflect the type of molecule. It will address the key aspects of the CTD, look at the CMC regulatory requirements during different stages of development, and discuss the importance of change control.

Rated by attendees to the public programme

Typically presented by Andrew Willis (bio)

Typical duration: 2 days
Pricing from £800 per attendee
Delivery: collaborative classroom

More @ IPI Academy

US FDA - Understanding Key Factors When Working with the FDA

In-house & bespoke training

This course has been designed to provide an essential overview of the critical factors when working with the FDA (Food and Drug Administration).  For those short on time this course is for you, as you will receive a focused and comprehensive overview of the key strategic considerations when making applications to the FDA.  

Typically presented by Andrew Willis (bio)

Typical duration: 1 day
Pricing from £450 per attendee
Delivery: collaborative classroom

More @ IPI Academy

Excellent, I am so please a colleague mentioned to IPI to me.

Julie Bailey, CFO, ILC Therapeutics Ltd

Content flow is well designed and good. [Parts I particularly liked were] process economy , Upstream and Downstream scale up.

Arindam Gupta, Global Category Procurement Manager, Servier Monde

I wanted to get short insight into biosimilar development process and I completely accomplished it.

Ainars Gavarans, , Olainfarm AS

Content was informative, I've learned many new details and subjects to consider. Speaker was fluent and interactive. I'll recommend this course to new QP's in the future.

Lian Abu-Obed, QP Trainee, Unipharm Limited

The speaker had lots of clarity in his explanations, making the course very easy to follow and understand, even with deep topics.

Bernardo Diaz, Regulatory Affairs Manager, Bioeq AG

I thought all the speakers were excellent. You could tell that they all really knew there subject matter and were so passionate in the way they delivered the content. Special mention has to go to Adekunle - fantastic course leader and so knowledgeable and made the 3 days very interactive.

Mark Kalinowski, Chief Financial officer, Albumedix Ltd

Good webinar, presentation and excellent speakers

Nor Hazwan Ali, Head of Regulatory Affairs,

The course was good and it was a pleasure to learn from the speakers. I wanted to get an overview of research and development of drugs and pharmaceuticals. I think this was achieved.

Sarah Kanna, Senior Legal Associate, Hevolution Foundation

It felt comprehensive.
An excellent resource going forward.

James McCracken, Quality Audit Manager , Advanz Pharma

Webinar was good, informative and lots of information. Speakers are well knowledgeable about Biosimilar Industry.

Srikanth Varma Kc, Global Audit and Due Diligence QA Manager, Abbott